![](https://investorshub.advfn.com/uicon/341783.png?cb=1583853296)
Tuesday, January 01, 2013 4:20:21 PM
The article isn't what most here want to read but I read all the comments and this on was the best. http://seekingalpha.com/article/1088281-why-arena-pharmaceuticals-will-underperform-in-2013?source=email_rt_article_readmore&ifp=0
Personally I like the length of time it's taking to go from FDA approval to market. It gives time for awareness to spread. I noticed in the comments multiple doctors posting and some providing their names/locations for verification. Hopefully they buy some shares, that will surely motivate them to write scripts and tell colleagues.
Here's the comment
vigsteven
From Doctor Steven Vig:
You said that the launch will target specialists but not general practitioners. That is not true. I called my Eisai drug rep (Tom) today (12 31 2013) who indicated that he will be mainly targeting primary care doctors, including family practice and internal medicine doctors. In his territory, the primary care doctors will be about 90% of his targeted doctors. He will be seeing several endocrine doctors , and some other specialists, but the majority of his targeted doctors are primary care.
On one typical day in my clinic, I carefully looked at each of the 20 patients that I saw that day, and found that 9/20 (45%) were potential candidates for Belviq, based on the BMI and comorbidities like diabetes, high blood pressure, and high lipids. This included overweight and obese patients and type two diabetics. I have many patients who are already waiting for the launch of Belviq, which I would anticipate around March of 2013.
I think that Belviq will be a blockbuster drug.
Steven Vig md internal medicine Tucson, Arizona
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM